Biotech Values

[turtlepower]

ECYT -

Endocyte will be responsible for the majority of funding and completion of the PROCEED trial

I assume this means that the trial enrollment size will be increased to include a substantial number of FR+ patients. I initially thought it meant there would be a 2nd trial with just FR++ patients and a small number of FR+ patients based on PFS as the PE but the PR doesn't indicate a 2nd trial is in the offing. A second trial showing significant PFS results would improve the approvability odds since EC145 showed significant PFS results in the FR++ patients in both sets of scans.

Overall it looks like an impressive deal and, based on the terms, a better deal than the one THLD signed with Merck KGaA.